Global active pharmaceutical ingredients market will reach $334 billion by 2028, growing by 6.9% annually over 2021-2028, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.
Highlighted with 146 tables and 104 figures, this 254-page report 鈥淕lobal Active Pharmaceutical Ingredients (API) 麻豆原创 2021-2028 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global active pharmaceutical ingredients market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2028 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global active pharmaceutical ingredients market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Region.
Based on Synthesis, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Synthetic API
鈥� Branded Synthetic API
鈥� Generic Synthetic API
Biotech API by Drug Type:
鈥� Monoclonal Antibodies
鈥� Recombinant Proteins
鈥� Vaccines
鈥� Other Biotech APIs
Biotech API by Customer Base:
鈥� Innovative Biologic API
鈥� Generic Biosimilar API
Biotech API by Expression Technology:
鈥� Mammalian Expression
鈥� Microbial Expression
鈥� Yeast Expression
鈥� Insect Expression
鈥� Other Expression Technologies
HPAPI
鈥� Branded HPAPI
鈥� Generic HPAPI
Based on Manufacturing Process, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Captive Manufacturing
鈥� Branded Captive API
鈥� Generic Captive API
Merchant Manufacturing by Drug Type:
鈥� Branded Merchant API
鈥� Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
鈥� Merchant Synthetic API
鈥� Merchant Biotech API
By Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Ophthalmology
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Pulmonary Disorders
鈥� Orthopedics
鈥� Other Applications
By Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
鈥� Branded Prescription Drugs
鈥� Generic Prescription Drugs
鈥� OTC Drugs
Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Indonesia, Malaysia, New Zealand, Singapore, Thailand, and Vietnam)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2018-2028. The breakdown of all regional markets by country and split of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application, over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 12
1.1 Industry Definition and Research Scope 12
1.1.1 Industry Definition 12
1.1.2 Research Scope 13
1.2 Research Methodology 16
1.2.1 Overview of 麻豆原创 Research Methodology 16
1.2.2 麻豆原创 Assumption 17
1.2.3 Secondary Data 17
1.2.4 Primary Data 17
1.2.5 Data Filtration and Model Design 18
1.2.6 麻豆原创 Size/Share Estimation 19
1.2.7 Research Limitations 20
1.3 Executive Summary 21
2 麻豆原创 Overview and Dynamics 23
2.1 麻豆原创 Size and Forecast 23
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the 麻豆原创 26
2.2 Major Growth Drivers 33
2.3 麻豆原创 Restraints and Challenges 41
2.4 Emerging Opportunities and 麻豆原创 Trends 44
2.5 Porter鈥檚 Fiver Forces Analysis 48
3 Segmentation of Global 麻豆原创 by Synthesis 52
3.1 麻豆原创 Overview by Synthesis 52
3.2 Synthetic API 54
3.2.1 Branded Synthetic API 55
3.2.2 Generic Synthetic API 56
3.3 Biotech API 57
3.3.1 Biotech API by Drug Type 58
3.3.1.1 Monoclonal Antibodies 59
3.3.1.2 Recombinant Proteins 60
3.3.1.3 Vaccines 61
3.3.1.4 Other Biotech APIs 62
3.3.2 Biotech API by Category 63
3.3.2.1 Innovative Biologic API 64
3.3.2.2 Generic Biosimilar API 65
3.3.3 Biotech API by Expression Technology 66
3.3.3.1 Mammalian Expression 67
3.3.3.2 Microbial Expression 68
3.3.3.3 Yeast Expression 69
3.3.3.4 Insect Expression 70
3.3.3.5 Other Expression Technologies 71
3.4 HPAPI 72
3.4.1 Branded HPAPI 73
3.4.2 Generic HPAPI 74
4 Segmentation of Global 麻豆原创 by Manufacturing Process 75
4.1 麻豆原创 Overview by Manufacturing Process 75
4.2 Captive Manufacturing 77
4.2.1 Branded Captive API 78
4.2.2 Generic Captive API 79
4.3 Merchant Manufacturing 80
4.3.1 Merchant Manufacturing by Drug Type 81
4.3.1.1 Branded Merchant API 82
4.3.1.2 Generic Merchant API 83
4.3.2 Merchant Manufacturing by Drug Synthesis 84
4.3.2.1 Merchant Synthetic API 85
4.3.2.2 Merchant Biotech API 86
5 Segmentation of Global 麻豆原创 by Therapeutic Application 87
5.1 麻豆原创 Overview by Therapeutic Application 87
5.2 Infectious Diseases 89
5.3 Oncology 90
5.4 Ophthalmology 91
5.5 Cardiovascular Disorders 92
5.6 Central Nervous System 93
5.7 Pulmonary Disorders 94
5.8 Orthopedics 95
5.9 Other Applications 96
6 Segmentation of Global 麻豆原创 by Drug Type 97
6.1 麻豆原创 Overview by Drug Type 97
6.2 Branded Prescription Drugs 99
6.3 Generic Prescription Drugs 100
6.4 OTC Drugs 101
7 Segmentation of Global 麻豆原创 by Region 102
7.1 Geographic 麻豆原创 Overview 2021-2028 102
7.2 North America 麻豆原创 2021-2028 by Country 107
7.2.1 Overview of North America 麻豆原创 107
7.2.2 U.S. 110
7.2.3 Canada 121
7.2.4 Mexico 123
7.3 European 麻豆原创 2021-2028 by Country 125
7.3.1 Overview of European 麻豆原创 125
7.3.2 UK 128
7.3.3 France 130
7.3.4 Germany 132
7.3.5 Spain 134
7.3.6 Italy 136
7.3.7 Russia 138
7.3.8 Rest of European 麻豆原创 140
7.4 Asia-Pacific 麻豆原创 2021-2028 by Country 142
7.4.1 Overview of Asia-Pacific 麻豆原创 142
7.4.2 China 145
7.4.3 Japan 147
7.4.4 India 150
7.4.5 Australia 152
7.4.6 South Korea 154
7.4.7 Rest of APAC Region 156
7.5 South America 麻豆原创 2021-2028 by Country 158
7.5.1 Argentina 161
7.5.2 Brazil 163
7.5.3 Chile 165
7.5.4 Rest of South America 麻豆原创 167
7.6 Rest of World 麻豆原创 2021-2028 by Country 168
7.6.1 UAE 171
7.6.2 Saudi Arabia 173
7.6.3 South Africa 175
7.6.4 Other National 麻豆原创s 177
8 Competitive Landscape 178
8.1 Overview of Key Vendors 178
8.2 New Product Launch, Partnership, Investment, and M&A 181
8.3 Company Profiles 182
AbbVie Inc. 182
Astrazeneca 184
Aurobindo Pharma Ltd. 189
BASF 192
Bayer AG 195
Boehringer Ingelheim 199
Catalent Inc. 204
Dr. Reddy's Laboratories 207
F. Hoffmann-La Roche 209
GlaxoSmithKline plc 211
Lonza Group 216
Lupin Limited 221
Merck & Co., Inc. 224
Mylan NV 227
Novartis International AG 230
Pfizer Inc. 233
Sanofi 238
Sun Pharmaceutical Industries Ltd. 241
Teva Pharmaceutical Industries Ltd. 244
Thermo Fisher Scientific 246
9 Investing in Global 麻豆原创: Risk Assessment and Management 248
9.1 Risk Evaluation of Global 麻豆原创 248
9.2 Critical Success Factors (CSFs) 251
Related Reports and Products 254
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
